Hormone Replacement in Menopausal Women With Epilepsy

Inclusion Criteria: * Subjects must have a diagnosis of partial epilepsy which has predated the onset of menopause. * Subjects must have between 0-10 seizures of any type per month. * Subjects must have had an EEG consistent with a partial epilepsy diagnosis, showing a focal abnormality. * Subjects must have had an imaging study of the brain since the diagnosis of epilepsy. * Subjects must be 1 year menopausal (without their menstrual periods), but within 5 years of their last menstrual period. * Subjects must be medically cleared by their primary care physician to take HRT. * Subjects must have had a normal PAP smear within the past 9 months. * Subjects must have had a mammogram without lesions suspicious for malignancy within the past 9 months. * Subjects or their caregivers must be able to keep an accurate seizure diary. * Subjects must be stable on their current AEDs for \>1 month. * Subjects must have not used HRT during the 3 months prior to enrollment. Exclusion Criteria: * Subjects with a history of breast, uterine or ovarian cancer. * Subjects with a treatable or reversible cause of recurrent seizures (metabolic, neoplastic, toxic or infectious causes). * Subjects with a history of deep vein thrombosis, arterial thrombosis, pulmonary embolus, blood clotting disorders, or stroke. * Subjects with elevated liver function test more than two time normal. * Subjects with 3 first degree family members who have a history of breast cancer. * Subjects with 1 first degree family member with a history of bilateral breast cancer. * Subjects with a history of complicated migraine headaches. * Subjects with a history of unexplained vaginal bleeding. * Subjects with a history of familial hyperlipoproteinemia. * Subjects with a history of myocardial infarction in the past 6 months. * Subjects with diabetes mellitus with vascular disease. * Subjects with untreated hypertension (\>145/95 on 3 occasions). * Subjects with a history of using an experimental drug or device in the past 30 days. * Subjects with severe chronic and/or progressive medical illnesses. * Subjects with active drug and alcohol abuse. * Subjects with a history of discontinuation of Prempro in the past due to side effects. * Subjects who state that they cannot tolerate 6 more months without relief of menopausal symptoms. * Subjects who plan to change or anticipate a change in their antiseizure treatment in the next 6 months.